why choose us

First received: May 15, 2023

Clinical Trial: Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Study Status: Completed

Recruit Status: RECRUITING

Condition: Blood Cancer

Study Type: INTERVENTIONAL


Official Title: Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Brief Summary: The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.

Read more